Logo

Worldwide Innovative Networking Consortium

Gene Expression Signature Under Development Predicts Lung Cancers Likely to Spread to Brain
Premium

At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.

WIN Consortium to Launch New Precision Oncology Study, Bank Samples for Blood Biomarker Discovery
Premium

On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.

NCI Projects Aim to Improve Tools, Pre-Clinical Models for Precision Oncology Research
Premium

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

HTG Molecular Posts 5 Percent Drop in Q2 Revenues

While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.

Illumina Joins WIN Consortium

Illumina is the latest to join the consortium, which is focused on personalizing cancer care.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.